Nasdaq · Healthcare
INCYTE CORP (INCY)
As-reported financials and recent SEC filings for INCYTE CORP, latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.
Snapshot
Revenue
$5.14B
Net income
$1.29B
Net margin
25.0%
Diluted EPS
$6.41
ROE
24.9%
P/E (TTM)
16.1×
Market cap
$22.73B
Debt / equity
—
Income statement (as reported)
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $5.14B | $4.24B | $3.70B | $3.39B | $2.99B |
| Gross profit | — | — | — | — | — |
| Operating income | $1.51B | $61.4M | $620.5M | $579.4M | $585.8M |
| Net income | $1.29B | $32.6M | $597.6M | $340.7M | $948.6M |
| Diluted EPS | $6.41 | $0.15 | $2.65 | $1.52 | $4.27 |
Source: company XBRL financial statements on SEC EDGAR.
Recent SEC filings
8-K2026-06-22
View on EDGAR →42026-06-10
View on EDGAR →42026-06-10
View on EDGAR →42026-06-10
View on EDGAR →42026-06-10
View on EDGAR →42026-06-10
View on EDGAR →42026-06-10
View on EDGAR →42026-06-10
View on EDGAR →Go deeper on INCY
Search INCYTE CORP’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.
Start freeData sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.